Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.5
Journals
Metabolites
Special Issues
Clinical Nutrition and Metabolic Diseases
share announcement

Clinical Nutrition and Metabolic Diseases

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: 15 June 2025 | Viewed by 2430

Special Issue Editors

Dr. Desirée Victoria-Montesinos

E-Mail Website
Guest Editor
Faculty of Pharmacy and Nutrition, UCAM Universidad Católica de Murcia, 30107 Murcia, Spain
Interests: nutrition; physiology; clinical nutrition; mediterranean diet; sport nutrition; clinical biochemistry
Special Issues, Collections and Topics in MDPI journals
Dr. Ana María García-Muñoz

E-Mail
Guest Editor
Faculty of Pharmacy and Nutrition, UCAM Universidad Católica de Murcia, 30107 Murcia, Spain
Interests: food; nutrition; nutrition health
Dr. José Francisco López-Gil

E-Mail Website
Guest Editor
1. One Health Research Group, Universidad de Las Américas, Quito 170124, Ecuador
2. Department of Communication and Education, Universidad Loyola Andalucía, 41704 Seville, Spain
Interests: nutrition; obesity; physical education; physical fitness; physical activity and health; eating behaviour
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Clinical nutrition and metabolic health are fundamental pillars of disease prevention, management, and overall well-being. The interplay between nutrition and metabolism is intricately linked to the onset and progression of numerous metabolic disorders. Malnutrition, whether due to deficiency or excess, and the dysregulation of metabolic pathways can lead to or exacerbate conditions such as obesity, diabetes, cardiovascular diseases, fatty liver disease, and metabolic syndrome. Conversely, targeted nutritional interventions can mitigate disease progression and enhance patient outcomes.

In recent years, advances in clinical research, metabolic profiling, and the development of innovative nutritional therapies have shed light on the mechanisms underlying nutrition-related metabolic disorders. However, the complexity of these interactions calls for further investigation to refine our understanding and treatment of these diseases. This Special Issue aims to gather high-quality original research and comprehensive reviews that explore the latest findings in clinical nutrition and metabolic diseases.

We invite submissions that address a broad range of topics, including but not limited to the role of diet in the prevention and management of metabolic diseases, the impact of specific nutrients on metabolic health, clinical trials of nutritional interventions, biomarkers of nutritional status in metabolic diseases, and the genetic and environmental factors influencing the nutrition–metabolism–disease nexus.

Dr. Desirée Victoria-Montesinos
Dr. Ana María García-Muñoz
Dr. José Francisco López-Gil
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical nutrition
  • metabolic disorders
  • nutritional intervention
  • metabolic health
  • disease prevention
  • biomarkers
  • nutritional therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 908 KiB  
Article
Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study
by Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada and Jose M. Arbones-Mainar
Metabolites 2024, 14(11), 618; https://doi.org/10.3390/metabo14110618 - 12 Nov 2024
Viewed by 1081
Abstract
Background: There are conflicting studies reporting both an increase and a decrease in vitamin B12 (VB12) levels in non-alcoholic fatty liver disease (NAFLD). In this study, we aimed to dissect the effects of steatosis and fibrosis on VB12. Methods: This is a cross-sectional [...] Read more.
Background: There are conflicting studies reporting both an increase and a decrease in vitamin B12 (VB12) levels in non-alcoholic fatty liver disease (NAFLD). In this study, we aimed to dissect the effects of steatosis and fibrosis on VB12. Methods: This is a cross-sectional study including all patients with a vibration-controlled transient elastography (VCTE) performed at the Hospital Miguel Servet (Zaragoza, Spain) between 2019 and 2022 for a chronic liver disease and having a recent blood test for VB12 levels. Liver fibrosis was assessed by VCTE and hepatic steatosis by ultrasonography and/or through controlled attenuation parameter (CAP). Results: 1195 patients (NAFLD n = 441, other chronic liver disease n = 754) were included. Median age was 57 years, 53% female. Patients with NAFLD had lower levels of VB12 compared to the rest of chronic liver diseases (289 vs. 313 pg/mL, p < 0.001). A significant negative correlation was observed between VB12 levels and hepatic steatosis measured by CAP (r = −0.13, p < 0.001). A significant positive correlation was observed between VB12 levels and liver stiffness in patients with NAFLD in both sexes (men r = 0.31, p < 0.001 and women r = 0.15, p = 0.016). A significant association between VB12 levels and liver fibrosis in cirrhosis stage was observed in patients with NAFLD (OR 1.06, 95% CI, 1.025–1.098, p = 0.001). Conclusion: VB12 levels were lower with greater hepatic steatosis. In NAFLD, VB12 levels were lower compared to other chronic liver diseases but their levels increased with higher liver stiffness and in cirrhosis stage. Full article
(This article belongs to the Special Issue Clinical Nutrition and Metabolic Diseases)
►▼ Show Figures

Figure 1

24 pages, 3202 KiB  
Article
Systematic Review and Meta-Analysis of Sclerocarya birrea on Metabolic Disorders: Evidence from Preclinical Studies
by Desirée Victoria-Montesinos, Pura Ballester, Pablo Barcina-Pérez and Ana María García-Muñoz
Metabolites 2024, 14(11), 615; https://doi.org/10.3390/metabo14110615 - 12 Nov 2024
Viewed by 1047
Abstract
Background/Objectives: Metabolic disorders, including diabetes, obesity, and cardiovascular diseases, are significant global health issues. Nutraceuticals, such as Sclerocarya birrea (SB), known for its high polyphenol content, are increasingly explored for managing these conditions. This study aims to evaluate the antihyperglycemic, hypolipidemic, and antihypertensive [...] Read more.
Background/Objectives: Metabolic disorders, including diabetes, obesity, and cardiovascular diseases, are significant global health issues. Nutraceuticals, such as Sclerocarya birrea (SB), known for its high polyphenol content, are increasingly explored for managing these conditions. This study aims to evaluate the antihyperglycemic, hypolipidemic, and antihypertensive effects of SB in animal models to understand its potential as a natural intervention for metabolic diseases. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. Searches across databases like PubMed, Web of Science, Embase, and Scopus identified studies using SB in animal models of metabolic disorders. Inclusion criteria were studies with SB intervention, control groups, and quantitative measures of metabolic parameters. The study was registered with INPLASY (INPLASY2024100031). Results: The meta-analysis revealed that SB significantly reduces blood glucose levels in diabetic animal models. Acute administration of SB showed a pooled standardized mean difference (SMD) of −7.13 (95% CI: −11.44 to −2.83) at 1 h and −9.75 (95% CI: −15.92 to −3.59) at 2–4 h post-administration. Chronic administration indicated a non-significant reduction in glucose levels (SMD: −5.69, 95% CI: −16.38 to 5.01). Conclusions: SB appears to have the potential for reducing blood glucose levels and may offer benefits for other cardiometabolic risk factors, including lipid profiles and oxidative stress. However, variability in the results underscores the need for further research, including standardized animal studies and clinical trials, to confirm these effects and clarify the mechanisms by which SB may impact metabolic disorders. Full article
(This article belongs to the Special Issue Clinical Nutrition and Metabolic Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop